814 related articles for article (PubMed ID: 17329466)
1. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; Reimherr F; Miller DD; McGee M; Khan A; Canive JM; Davis SM; Hsiao JK; Lieberman JA;
Schizophr Res; 2008 Mar; 100(1-3):39-52. PubMed ID: 18191383
[TBL] [Abstract][Full Text] [Related]
5. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
[TBL] [Abstract][Full Text] [Related]
6. What CATIE found: results from the schizophrenia trial.
Swartz MS; Stroup TS; McEvoy JP; Davis SM; Rosenheck RA; Keefe RS; Hsiao JK; Lieberman JA
Psychiatr Serv; 2008 May; 59(5):500-6. PubMed ID: 18451005
[TBL] [Abstract][Full Text] [Related]
7. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
8. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
[TBL] [Abstract][Full Text] [Related]
10. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
[TBL] [Abstract][Full Text] [Related]
12. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
[TBL] [Abstract][Full Text] [Related]
13. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Swartz MS; Perkins DO; Stroup TS; Davis SM; Capuano G; Rosenheck RA; Reimherr F; McGee MF; Keefe RS; McEvoy JP; Hsiao JK; Lieberman JA;
Am J Psychiatry; 2007 Mar; 164(3):428-36. PubMed ID: 17329467
[TBL] [Abstract][Full Text] [Related]
14. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
[TBL] [Abstract][Full Text] [Related]
15. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA;
N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647
[TBL] [Abstract][Full Text] [Related]
17. The CATIE schizophrenia effectiveness trial.
Delisi LE; Nasrallah HA
Schizophr Res; 2005 Dec; 80(1):v-vi. PubMed ID: 16291292
[No Abstract] [Full Text] [Related]
18. Effectiveness of switching antipsychotic medications.
Essock SM; Covell NH; Davis SM; Stroup TS; Rosenheck RA; Lieberman JA
Am J Psychiatry; 2006 Dec; 163(12):2090-5. PubMed ID: 17151159
[TBL] [Abstract][Full Text] [Related]
19. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
Mohamed S; Rosenheck RA; Lin H; Swartz M; McEvoy J; Stroup S
J Nerv Ment Dis; 2015 Jul; 203(7):486-92. PubMed ID: 26075840
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
Ramsey TL; Brennan MD
Schizophr Res; 2014 Dec; 160(1-3):73-9. PubMed ID: 25449714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]